9.12 Protocol Specific Research Support The University of Minnesota Cancer Center (UMCC) strongly supports the implementation of 'investigatorinitiated' clinical trials. These trials test novel therapeutic agents developed at our institution, or innovative application of currently available therapeutic agents. Seventy-seven local, investigator-initiated clinical trials have been implemented during the current funding period, .and an additional 15 are in the final stages of development. These trials test a variety of approaches including hematopoietic cell transplantation, nontransplant immunotherapy, novel combinations of chemo-therapy, multimodality therapy, and pharmacotherapeutic monitoring. At the University of Minnesota Cancer Center, investigator-initiated clinical research efforts exist across a wide spectrum of disciplines including cancer prevention, screening, and many therapeutic modalities. However, senior cancer center leadership has identified non-transplant cell and immune-based cancer therapy as the area of highest scientific priority for focused, protocol-specific research support during the current and proposed funding periods. This strategy builds on the historic strength of our Transplant Biology and Therapy Program and collaborations with the Immunology Program. It is supported by the Clinical Trials Office and by the Translational Therapy Shared Resource. When fully implemented, this approach is intended to address both hematologic malignancies and a variety of solid tumors in children and adults. Cancer Center leadership has selected several non-transplant cell or immune-based cancer therapy initiative for proposed protocol specific research support. Criteria for selection include innovation, progress, involvement of more than one Cancer Center program, use of Shared Resources, potential for therapeutic application to solid tumor malignancies and need for clinical trial support. In the proposed funding period, ongoing selection of highest scientific priority clinical research will be made by the Clinical Research Leadership Team (CRL) composed of senior cancer center leadership with expertise in translational and clinicalresearch. Recommendations concerning clinical trials of highest scientific priority will be ratified by the Cancer Center Executive Advisory Committee.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Minnesota Twin Cities
United States
Zip Code
Sarver, Aaron L; Murray, Collin D; Temiz, Nuri A et al. (2016) MYC and PVT1 synergize to regulate RSPO1 levels in breast cancer. Cell Cycle 15:881-5
Diep, Caroline H; Knutson, Todd P; Lange, Carol A (2016) Active FOXO1 Is a Key Determinant of Isoform-Specific Progesterone Receptor Transactivation and Senescence Programming. Mol Cancer Res 14:141-62
Yun, Young Sung; Kim, Kwan Hyun; Tschida, Barbara et al. (2016) mTORC1 Coordinates Protein Synthesis and Immunoproteasome Formation via PRAS40 to Prevent Accumulation of Protein Stress. Mol Cell 61:625-39
Yan, Y; Hanse, E A; Stedman, K et al. (2016) Transcription factor C/EBP-β induces tumor-suppressor phosphatase PHLPP2 through repression of the miR-17-92 cluster in differentiating AML cells. Cell Death Differ 23:1232-42
Beura, Lalit K; Hamilton, Sara E; Bi, Kevin et al. (2016) Normalizing the environment recapitulates adult human immune traits in laboratory mice. Nature 532:512-6
Than, B L N; Linnekamp, J F; Starr, T K et al. (2016) CFTR is a tumor suppressor gene in murine and human intestinal cancer. Oncogene 35:4179-87
Struntz, Nicholas B; Harki, Daniel A (2016) Catch and Release DNA Decoys: Capture and Photochemical Dissociation of NF-κB Transcription Factors. ACS Chem Biol 11:1631-8
Knorr, David A; Wang, Hongbo; Aurora, Mukta et al. (2016) Loss of T Follicular Helper Cells in the Peripheral Blood of Patients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 22:825-33
Glasgow, Michelle; Vogel, Rachel Isaksson; Burgart, Jennifer et al. (2016) Long term follow-up of a phase II trial of multimodal therapy given in a ""sandwich"" method for stage III, IV, and recurrent endometrial cancer. Gynecol Oncol Res Pract 3:6
Felices, Martin; Lenvik, Todd R; Davis, Zachary B et al. (2016) Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells. Methods Mol Biol 1441:333-46

Showing the most recent 10 out of 763 publications